Prospective patients, please visit our Patient’s page for the most up to date information on how to sign up for the Medical Cannabis Pilot Program (MCPP) and the Opioid Alternative Pilot Program (OAPP) to access medical cannabis.
On August 28th, 2018, Governor Bruce Rauner signed Senate Bill 336, the Alternatives to Opioids ...read more
Governor Rauner Signs Senate Bill 336
New Changes for Medical Cannabis Patients in Illinois
On August 28, 2018, Governor Bruce Rauner signed Senate Bill 336, the Alternatives to Opioids Act of 2018, which amends the Compassionate Use of Medical Cannabis Pilot Program Act, into law. There are several components to the provisions of Senate Bill ...read more
Two studies published in the Journal of the American Medical Association found states with medical cannabis laws greatly reduce reliance on prescription opiates. In both studies, after enacting medical cannabis laws, states saw opiate prescriptions from Medicare Part D recipients drop by 2.21 million daily doses and 3.74 million daily ...read more
On January 16th, 2018, an Illinois Judge ordered the Department of Public Health to add intractable pain to the list of qualifying conditions under the Medical Cannabis Pilot Program. The spokesperson for the Department announced that they plan to appeal that ruling. Find more about the Illinois ruling here.
As more ...read more
A collaborative study between Universities in Israel and Germany found the Endocannabinoid System (ECS) to have a homeostatic effect on body mechanisms that determine aging. This modulation of the underlying physical properties that regulate and determine aging has long thought to have been connected; however previously, no direct links between ...read more
A research study published in the American Journal of Psychiatry showed Cannabidiol (CBD) to have positive effects on patients suffering from Schizophrenia. In a double blind study, patients were given either a placebo or 1g/day of CBD and assessed before and after treatment using several standard methodologies and metrics for ...read more
A cannabis research study based out of Michigan State University (MSU) found the anti-inflammatory properties of cannabis, specifically THC, help alleviate chronic inflammation in the brain in HIV patients. A reduction in the white blood cells called monocytes as well as their protein byproducts was seen more often in patients ...read more
A California based study recently demonstrated that the active component of marijuana, Δ 9 -tetrahydrocannabinol (THC), competitively inhibits the enzyme acetylcholinesterase (AChE) as well as prevents AChE-induced amyloid β-peptide (Aβ) aggregation, the key pathological marker of Alzheimer's disease. These markers bond to neurons in the brain and are one of ...read more
A group of researchers from the University of California, Berkeley and Kent State University analyzed a set of 2,897 patient reported outcomes regarding cannabis and its use in pain relief in conjunction with opiates.
"... this study can conclude that medical cannabis patients report successfully using cannabis along with or as ...read more
A double-blind, placebo-controlled human trial, published in the New England Journal of Medicine, found cannabidiol can decrease the frequency of convulsive seizures. 120 patients with Dravet syndrome were given orally administered cannabinoids. During the 14-week study, the cannabidiol groups average seizure frequency per month decreased from 12.4 to 5.9. On ...read more